Related Experiment Video

Updated: Jun 13, 2025

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
06:12

Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum

Published on: May 3, 2024

1.7K

Protective role of TRPM7 knockdown in ulcerative colitis via blocking NLRP3 inflammasome-mediated pyroptosis

Jinzhen Peng1, Shuai Tang1, Lifang Huang2

  • 1Department of gastroenterology, Shaoguan First People's Hospital, Shaoguan 512000, PR China.

Prostaglandins & Other Lipid Mediators
|September 11, 2024
PubMed

Insights

Targeting TRPM7 (Transient Receptor Potential Melastatin 7) shows therapeutic potential for ulcerative colitis (UC). Reducing TRPM7 alleviates inflammation and gut barrier damage by inhibiting NLRP3-dependent pyroptosis.

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Transient receptor potential melastatin 7 (TRPM7) exhibits ion channel and kinase functions, making it a potential target for immunomodulation.
  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease with complex underlying mechanisms.

Purpose of the Study:

  • To investigate the role of TRPM7 in the pathogenesis of ulcerative colitis (UC).
  • To elucidate the molecular mechanisms by which TRPM7 influences UC progression.

Main Methods:

  • Established in vivo murine and in vitro cell models of UC using DSS stimulation.
  • Assessed TRPM7 expression via RT-qPCR and Western blotting.
  • Evaluated colonic damage, inflammation, oxidative stress, and intestinal barrier function using various assays (H&E, DAI, MPO, ELISA, FITC-dextran flux, TEER).
  • Investigated NLRP3-dependent pyroptosis using immunofluorescence and Western blotting.

Main Results:

  • TRPM7 depletion significantly reduced inflammation, oxidative damage, and intestinal barrier dysfunction in both in vitro and in vivo UC models.
  • Silencing TRPM7 suppressed NLRP3 inflammasome-mediated pyroptosis.
  • Administration of an NLRP3 agonist partially reversed the protective effects of TRPM7 silencing.

Conclusions:

  • TRPM7 plays a crucial role in UC development.
  • TRPM7 deletion demonstrates therapeutic potential for UC by inhibiting NLRP3-dependent pyroptosis.
  • Targeting TRPM7 may offer a novel therapeutic strategy for managing ulcerative colitis.
Keywords:
Intestinal barrier disruptionNLRP3 inflammasomePyroptosisTRPM7Ulcerative colitis

More Related Videos

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.7K
Evaluation of Caspase Activation to Assess Innate Immune Cell Death10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

3.2K

Related Concept Videos

Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
961
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120